Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

NCT06563245 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

96

Enrollment

NETWORK

Sponsor class

Conditions

Classical Hodgkin Lymphoma
Child
Adolescent
Young Adult
Metabolic Response
Survival
Treatment
Brentuximab Vedotin
PET Scan

Interventions

DRUG: Brentuximab Vedotin for Injection
RADIATION: response-adapted radiation
DRUG: Doxorubicin
DRUG: Etoposide
DRUG: Prednisone
DRUG: Cyclophosphamide
DRUG: Dacarbazine
DRUG: Tislelizumab Injection
DRUG: Bedamustine

Sponsor

Children's Cancer Group, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]